{"id":55257,"date":"2023-03-28T14:07:50","date_gmt":"2023-03-28T12:07:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/"},"modified":"2023-03-28T14:07:50","modified_gmt":"2023-03-28T12:07:50","slug":"prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/","title":{"rendered":"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease"},"content":{"rendered":"
\n

\nPROOF-HD is the only late-stage study in Huntington\u2019s disease targeting clinical progression; topline results expected in early Q2 2023<\/i>\n<\/p>\n

NAARDEN, Netherlands and WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V.,<\/a> a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced that the last participant in PROOF-HD, a global Phase 3 study in Huntington\u2019s disease (HD), has completed the last planned visit of the blinded treatment period, marking the completion of the main study. Almost all patients (98 percent) that were eligible elected to continue in the ongoing open-label extension of PROOF-HD. Topline results of the PROOF-HD study are expected in early Q2 2023.\n<\/p>\n

<\/a><\/p>\n

\nThe PROOF-HD study has been conducted with the Huntington Study Group (HSG)<\/a>, a world leader in clinical research for HD<\/a> and valued collaborator for Prilenia.\n<\/p>\n

\n\u201cThere is an urgent need for treatments that can alter the course of HD and bring hope to individuals and families impacted by the disease,\u201d said Dr. Michael R. Hayden, CEO and Founder of Prilenia. \u201cOur team is working diligently to bring topline results to the community as quickly as possible. We thank the Huntington Study Group and their partners, study investigators, and most importantly study participants and their families for their contribution to this important research.\u201d\n<\/p>\n

\nPROOF-HD is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of pridopidine (45 mg twice daily for 65 to 78 weeks), an oral, highly selective and potent investigational sigma-1 receptor (S1R) agonist, in individuals with HD. The aim of the study is to evaluate pridopidine\u2019s ability to preserve the functional ability of individuals living with HD, with a primary endpoint of a change from baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) score at 65 weeks. The trial enrolled 499 individuals and was conducted in the U.S., Canada, Austria, Czech Republic, France, Germany, Italy, the Netherlands, Poland, Spain and the United Kingdom. The study was completed on time and as planned.\n<\/p>\n

\nAbout Pridopidine<\/b>\n<\/p>\n

\nPridopidine (45 mg twice daily) is an oral, highly selective and potent investigational S1R agonist that has exhibited a safety and tolerability profile similar to placebo in clinical studies to date. The S1R protein is highly expressed in the brain and spinal cord where it regulates several key processes that are commonly impaired in various neurodegenerative diseases. Activation of the S1R by pridopidine stimulates multiple cellular pathways, including autophagy, axonal transport, mitochondrial energy production, and calcium homeostasis which are essential to neuronal function and survival and may lead to neuroprotective effects.\n<\/p>\n

\nPrilenia holds Orphan Drug designation for pridopidine in HD and ALS in the U.S. and EU. In addition, pridopidine has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD.\n<\/p>\n

\nAbout Prilenia<\/b>\n<\/p>\n

\nPrilenia is a clinical stage biotechnology company founded in 2018 focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders.\n<\/p>\n

\nPrilenia is backed by a group of well-respected investors including: Forbion, Morningside, Sands Capital, SV Health Investors, Sectoral Asset Management, Talisman, Amplitude Ventures and the ALS Investment Fund. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Waltham, Massachusetts in the U.S.\n<\/p>\n

\nFor more information visit www.prilenia.com<\/a> and follow us on LinkedIn<\/a> and Twitter.<\/a>\n<\/p>\n

\nAbout Huntington Study Group \/ HSG Clinical Research, Inc.<\/b>\n<\/p>\n

\nFounded in 1993 in Rochester, NY, the Huntington Study Group (HSG) is a not-for-profit organization composed of the world\u2019s first and largest collaborative network of over 800 experts in Huntington\u2019s disease at more than 130 HSG credentialed research sites worldwide. HSG Clinical Research, Inc., a wholly owned subsidiary of the HSG, is a full-service clinical research organization that specializes in conducting HD trials. The HSG also offers educational services for healthcare professionals and care providers on treating patients with HD. For more information, visit www.huntingtonstudygroup.org<\/a>.\n<\/p>\n

\n\u00a9<\/sup>2023 Prilenia Therapeutics B.V.\n<\/p>\n

\nFor a copy of this release, visit Prilenia\u2019s website at www.prilenia.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPrilenia Contact
\n
Kristina Coppola
\n
Head of Corporate Communications
\n
info@prilenia.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PROOF-HD is the only late-stage study in Huntington\u2019s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced that the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55257","6":"format-standard","7":"category-industry"},"yoast_head":"\nPrilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PROOF-HD is the only late-stage study in Huntington\u2019s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced that the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T12:07:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230321005915\/en\/744456\/21\/LOGO_Prilenia_HIGH_RESO-02.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease\",\"datePublished\":\"2023-03-28T12:07:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/\"},\"wordCount\":697,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005915\\\/en\\\/744456\\\/21\\\/LOGO_Prilenia_HIGH_RESO-02.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/\",\"name\":\"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005915\\\/en\\\/744456\\\/21\\\/LOGO_Prilenia_HIGH_RESO-02.jpg\",\"datePublished\":\"2023-03-28T12:07:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005915\\\/en\\\/744456\\\/21\\\/LOGO_Prilenia_HIGH_RESO-02.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005915\\\/en\\\/744456\\\/21\\\/LOGO_Prilenia_HIGH_RESO-02.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/","og_locale":"en_US","og_type":"article","og_title":"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease - Pharma Trend","og_description":"PROOF-HD is the only late-stage study in Huntington\u2019s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced that the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-28T12:07:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230321005915\/en\/744456\/21\/LOGO_Prilenia_HIGH_RESO-02.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease","datePublished":"2023-03-28T12:07:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/"},"wordCount":697,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230321005915\/en\/744456\/21\/LOGO_Prilenia_HIGH_RESO-02.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/","url":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/","name":"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230321005915\/en\/744456\/21\/LOGO_Prilenia_HIGH_RESO-02.jpg","datePublished":"2023-03-28T12:07:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230321005915\/en\/744456\/21\/LOGO_Prilenia_HIGH_RESO-02.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230321005915\/en\/744456\/21\/LOGO_Prilenia_HIGH_RESO-02.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/prilenia-achieves-last-patient-last-visit-in-phase-3-proof-hd-clinical-study-for-huntingtons-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55257"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55257\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}